Merck KGaA and Jerini Announce Collaboration to Develop Small Molecule Cancer Drugs
Prior to the agreement, Jerini identified novel proprietary small molecule lead series by applying its Peptides-to-Drugs (P2D) approach. Merck and Jerini are joining forces to further develop Jerini's compounds. Initiation of pre-clinical development is planned for 2005.
Under terms of the agreement, Jerini will receive an upfront payment, personnel funding, milestone payments, and royalties. Merck obtains worldwide rights for all indications in cancer, cardiovascular diseases, diabetes and thyroid disorders. Jerini could receive in excess of EUR 50 million if the product is approved. Further financial details were not disclosed.
Organizations
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.